poster

Zuranolone in Major Depressive Disorder (MDD): Minimal Important Difference (MID) and Meaningful Change Threshold (MCT) on the 17-item Hamilton Rating Scale for Depression (HAMD-17)

Abstract: Objective: WATERFALL (Phase 3; NCT04442490), adult patients with moderate to severe MDD who received zuranolone 50mg vs placebo showed statistically significant improvement in d...

01/19/2023

Real-World Safety Profile of Esketamine Nasal Spray During the First 12 Treatment Sessions: An Analysis at 34 Months After Approval

Abstract: Purpose: To examine real-world esketamine nasal spray (ESK) treatment-emergent adverse events (TEAEs) of interest (i.e., sedation, dissociation, increased blood pressure [BP]) a...

01/19/2023

Clinical, Economic, and Humanistic Outcomes Associated With Obesity Among Adults With Bipolar I Disorder: Analysis of National Health and Wellness Survey Data

Abstract: Background: People living with bipolar I disorder (BD-I) have a higher risk of obesity than the general population. While outcomes associated with obesity are well documented in...

01/19/2023

The NP Psych Navigator: A Multimedia Website for Nurse Practitioners Who Treat Patients With Mental Health Disorders

Abstract: Background: Psychiatric nurse practitioners (NPs) need access to appropriate, up-to-date educational materials to help them successfully diagnose and clinically manage their pat...

01/19/2023

Assessing the Need for Repeat Treatment Courses with Zuranolone in Adult Patients With Major Depressive Disorder With Elevated Anxiety: An Analysis of the Open-Label, Phase 3 SHORELINE Study

Abstract: Introduction Zuranolone is an investigational neuroactive steroid and positive allosteric modulator of synaptic and extrasynaptic GABAA receptors in clinical development as an o...

01/19/2023

Effect of daridorexant on sleep and daytime functioning in older adults with insomnia disorder

Abstract: As insomnia affects elderly more than younger adults, therapeutic options with limited safety risks are needed to treat this patient group. We report elderly subgroup analyses f...

01/19/2023

Trazodone prescribing in insomnia: a real-world cohort study

Abstract: Trazodone is indicated for depressive disorder (150-400 mg/day) but is often prescribed off-label to treat insomnia at “low dose” (

01/19/2023

Incremental Economic Burden Associated with Insomnia Among Patients with Type 2 Diabetes in the United States: A Retrospective Claims Database Analysis

Abstract: Background: While insomnia occurs in half of adults with type 2 diabetes (T2D), its incremental economic impact in this population is unclear.

01/19/2023

Incremental Healthcare Costs of Insomnia Among Adult Patients With Alzheimer’s Disease or Related Dementias in the United States

Abstract: Background: Insomnia contributes to cognitive decline, increased fall risk, and nursing home placement in patients with Alzheimer’s disease and related dementias (ADRD). Obje...

01/19/2023

Effect of Lumateperone (ITI-007) on Quality of Life and Functional Disability in the Treatment of Bipolar Depression

Abstract: Background: Lumateperone is an FDA-approved antipsychotic to treat schizophrenia and depressive episodes associated with bipolar I or bipolar II disorder. In a Phase 3 clinical ...

01/19/2023

Tracks

Major Depressive Disorder

General Psychiatry

ADHD

MDD Insights

Schizophrenia Insights

About

Celebrating 35 years of empowering the highest standard in mental healthcare, Psych Congress serves as a unique, integrated forum to connect members of the entire mental health team—bringing together psychiatrists, nurse practitioners, physician assistants, psychologists, primary care physicians, and other mental health professionals for 4 days of practical education to improve patient care.

December 9 ⁠–⁠ December 11

March 31 ⁠–⁠ April 2

April 21 ⁠–⁠ April 24

May 28 ⁠–⁠ May 31

See Full Calendar

poster

Tracks

About

Specialties

Events

Year Round Education

HMP Global Products